SCHEMBL4080277

SCHEMBL4080277

C[Si](C)(C)OC(=O)C1=CC2CCC1C2

nearest known ligand 0.38

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31064743 0.82 SLC6A3 (0.40) CYP19A1
SCHEMBL996860 0.82 SLC6A3 (0.40) CYP19A1
SCHEMBL29723671 0.82 SLC6A3 (0.40) CYP19A1
SCHEMBL3926283 0.82 SLC6A3 (0.40) CYP19A1
SCHEMBL29723645 0.82 SLC6A3 (0.40) CYP19A1
SCHEMBL601985 0.82 CYP19A1 (0.38) CYP19A1
SCHEMBL2000716 0.80 CYP19A1 (0.36) CYP19A1
SCHEMBL7741611 0.79 CYP19A1 (0.36) CYP19A1
SCHEMBL511962 0.78 HSD11B1 (0.34) CYP19A1
SCHEMBL4247813 0.78 TSHR (0.38) CYP19A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108473972-A Drimenol synthase III 弗门尼舍有限公司 2018-08-31 CN disclosed
CN-102718759-A Heterocyclic CETP inhibitors BRISTOL MYERS SQUIBB CO 2012-10-10 CN disclosed
CN-101675069-A Method for producing fine chemicals METANOMICS GMBH 2010-03-17 CN disclosed
WO-2009120815-A2 THERAPEUTIC COMPOSITIONS AND METHODS BOSTON BIOCOM, LLC (US) 2009-10-01 WO disclosed
CN-101528699-A Heterocyclic cetp inhibitors BRISTOL MYERS SQUIBB CO (US) 2009-09-09 CN disclosed
CN-101421412-A Process for the production of fine chemicals METANOMICS GMBH (DE) 2009-04-29 CN disclosed
CN-101356161-A Heterocyclic CETP inhibitors BRISTOL MYERS SQUIBB CO (US) 2009-01-28 CN disclosed
CN-1795177-A 1, 2, 4-substituted 1, 2, 3, 4-tetrahydro-and 1, 2 dihydro-quinolines and 1, 2, 3, 4-tetrahydro-quinoxaline derivatives as CETP inhibitors for the treatment of atherosclerosis and obesity PFIZER PROD INC (US) 2006-06-28 CN disclosed
EP-1583834-A1 GENE EXPRESSION INDUCING FUSION PROTEIN AND METHOD FOR CONTROLLING GENE EXPRESSION INDUCTION Millegen (FR) 2005-10-12 EP disclosed
WO-2004067745-A1 GENE EXPRESSION INDUCING FUSION PROTEIN AND METHOD FOR CONTROLLING GENE EXPRESSION INDUCTION MILLEGEN (FR) 2004-08-12 WO disclosed